pharmaphorum8d
ASH: CRISPR, Vertex' CTX001 hits the mark in red cell disorders
and analysts at EvaluateVantage have suggested that CTX001 could become a $1.3 billion product if it gets approved for both indications. In October, CRISPR Therapeutics co-founder Emmanuelle ...
Crispr Therapeutics price target raised to $56 from $55 at Barclays
Barclays analyst Gena Wang raised the firm’s price target on Crispr Therapeutics (CRSP) to $56 from $55 and keeps an Equal Weight rating on the ...
Crispr Therapeutics price target raised to $120 from $100 at Truist
Truist raised the firm’s price target on Crispr Therapeutics (CRSP) to $120 from $100 and keeps a Buy rating on the shares. The company’s Q4 ...
Seeking Alpha28d
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...